Quantcast
Channel: cafepharma - hepatitis
Browsing all 29 articles
Browse latest View live

Dynavax finishes 2,400-patient hepatitis vaccine test

Dynavax finishes 2,400-patient hepatitis vaccine test Bizjournals.com

View Article



Teva Faces Second Trial Over Hepatitis Cases Linked to Drug

Teva Faces Second Trial Over Hepatitis Cases Linked to Drug Bloomberg

View Article

Teva Not Responsible for Nevada Hepatitis Outbreak, Lawyer Tells Jurors

Teva Not Responsible for Nevada Hepatitis Outbreak, Lawyer Tells Jurors Bloomberg

View Article

Hepatitis Testing Company Taking Off

Hepatitis Testing Company Taking Off The Street

View Article

Inhibitex Auction Shows Battle for Hepatitis Drugs

Inhibitex Auction Shows Battle for Hepatitis Drugs Minyanville

View Article


OraSure Technologies Announces Rapid HCV Testing Initiatives for First...

OraSure Technologies Announces Rapid HCV Testing Initiatives for First National Hepatitis Testing Day Yahoo/GlobeNewswire

View Article

Aethlon Medical Announces Expanded Access to Hemopurifier® Therapy For...

Aethlon Medical Announces Expanded Access to Hemopurifier® Therapy For Individuals Infected with Hepatitis C Virus (HCV) Yahoo/PRNewswire

View Article

OraSure Technologies Applauds New CDC Recommendations That All Baby Boomers...

OraSure Technologies Applauds New CDC Recommendations That All Baby Boomers be Tested for Hepatitis C Yahoo/GlobeNewswire

View Article


Gilead-Bristol Hepatitis C Drug Combo Cures 100% in Study

Gilead-Bristol Hepatitis C Drug Combo Cures 100% in Study Bloomberg

View Article


Idenix Pharma Initiates Phase II Study

Idenix Pharma Initiates Phase II Study Yahoo/Zacks

View Article

Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the...

Gilead Announces U.S. FDA Priority Review Designation for Sofosbuvir for the Treatment of Hepatitis C Yahoo/BusinessWire

View Article

Three Future Winners and One Major Loser in the HCV Wars

Three Future Winners and One Major Loser in the HCV Wars Motley Fool

View Article

Vertex Says U.S. Places Partial Hold on Hepatitis Study

Vertex Says U.S. Places Partial Hold on Hepatitis Study Bloomberg

View Article


Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex

Why Idenix Could Rise Even Higher, and Challenge Gilead and Vertex Yahoo/24-7 Wallstreet

View Article

Merck Announces Presentation of Interim Data from Study of Investigational...

Merck Announces Presentation of Interim Data from Study of Investigational Combination of HCV Therapies MK-5172 and MK-8742 at the 2013 American Association for the Study of Liver Diseases (AASLD)...

View Article


Bristol seeks Japan approval of all-oral hepatitis C treatment

Bristol seeks Japan approval of all-oral hepatitis C treatment Yahoo/Reuters

View Article

Gilead Sciences and Johnson & Johnson Push Vertex Out of Hepatitis C Race

Gilead Sciences and Johnson & Johnson Push Vertex Out of Hepatitis C Race Motley Fool

View Article


New GT-1b Data from ABT-450 Containing Regimen Being Presented at The Liver...

New GT-1b Data from ABT-450 Containing Regimen Being Presented at The Liver Meeting Yahoo/BusinessWire

View Article

J&J, Medivir Win U.S. FDA Approval for Hepatitis C Pill

J&J, Medivir Win U.S. FDA Approval for Hepatitis C Pill Bloomberg

View Article

Gilead And AbbVie Battle For Top Spot In $20 Billion Hepatitis Drug Market

Gilead And AbbVie Battle For Top Spot In $20 Billion Hepatitis Drug Market Seeking Alpha

View Article
Browsing all 29 articles
Browse latest View live




Latest Images